Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo

Wells Fargo released its annual biopharma M&A screen this week, including weight loss drug developer Viking Therapeutics (VKTX) and gene editing firms CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) in its list of potential acquisition targets for 2024.

The investment